Arrivent Biopharma Inc expected to post a loss of 70 cents a share - Earnings Preview

ArriVent BioPharma

11/08/2025 12:03

Arrivent Biopharma Inc AVBP.OQ AVBP.O is expected to  show no change in quarterly revenue when it reports  results on August 13 (estimated) for the period ending June 30 2025

‚ÄčLSEG's mean analyst estimate for Arrivent Biopharma Inc is for a loss of 70 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Arrivent Biopharma Inc is $40.00, about 55% above its last closing price of $17.99

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.66
-0.66
-1.90
Missed
-186.1
Dec. 31 2025
-0.78
-0.78
-0.61
Beat
21.5
Sep. 30 2024
-0.72
-1.00
-0.61
Beat
39.1‚Äč
Jun. 30 2024
-0.65
-0.64
-0.65
Missed
-1
‚Äč‚ÄčMar. 31 2024
-1.09
-1.10
-0.70
Beat
36.2
‚Äč

This summary was machine generated August 11 at 11:03 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)